We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$580M
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+4.88%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$198M
AUM Growth
-$30.2M
(-13%)
Cap. Flow
-$17.6M
Cap. Flow
% of AUM
-8.86%
Top 10 Holdings %
Top 10 Hldgs %
61.84%
Holding
46
New
8
Increased
13
Reduced
18
Closed
7
Avg Time Held Equity + Options
2.6
quarters
Top 10 Avg Time Held Equity + Options
2
quarters
Top 20 Avg Time Held Equity + Options
2.1
quarters
Avg Time Held Equity only
2.6
quarters
Top 10 Avg Time Held Equity only
2
quarters
Top 20 Avg Time Held Equity only
2.2
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kura Oncology
KURA
|
+$11.5M |
| 2 |
Q32 Bio
QTTB
|
+$8.06M |
| 3 |
uniQure
QURE
|
+$7.65M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$5.94M |
| 5 |
SBBP
Strongbridge Biopharma plc.
SBBP
|
+$5.92M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$16.7M |
| 2 |
WCG
Wellcare Health Plans, Inc.
WCG
|
+$9.43M |
| 3 |
HNGR
Hanger Inc.
HNGR
|
+$8.55M |
| 4 |
Iovance Biotherapeutics
IOVA
|
+$7.79M |
| 5 |
NEVRO CORP.
NVRO
|
+$7.33M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.24% |
| 2 | Technology | 0.92% |
| 3 | Miscellaneous | 0.84% |
| 4 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
DELISTED
Molecular Templates, Inc.
MTEM
| $1.65M | 0.83% |
13,179
-6,674
| -34% | -$725K |
2019 Q1
1 quarter
|
|
27
Evolus
EOLS
$496M
| $1.65M | 0.83% |
+112,590
| New | +$2.23M |
2019 Q2
0 quarters
|
|
28
Personalis
PSNL
$1.69B
| $1.53M | 0.77% |
+56,446
| New | +$1.6M |
2019 Q2
0 quarters
|
|
|
SRRA
29
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $1.5M | 0.76% |
67,040
+5,598
| +9% | +$271K |
2018 Q1
5 quarters
|
|
|
UROV
30
DELISTED
Urovant Sciences Ltd.
UROV
| $1.13M | 0.57% |
142,620
+42,750
| +43% | +$351K |
2019 Q1
1 quarter
|
|
|
ARQL
31
DELISTED
Arqule Inc
ARQL
| $921K | 0.46% |
+83,675
| New | +$582K |
2019 Q2
0 quarters
|
|
32
Tempest Therapeutics
TPST
$11.5M
| $854K | 0.43% |
379
-1,010
| -73% | -$2.97M |
2018 Q3
3 quarters
|
|
33
DELISTED
ModivCare
MODV
| $842K | 0.42% |
14,677
-37,647
| -72% | -$2.44M |
2018 Q3
3 quarters
|
|
34
ADMA Biologics
ADMA
$2.31B
| $719K | 0.36% |
+185,721
| New | +$820K |
2019 Q2
0 quarters
|
|
|
35
DELISTED
NEVRO CORP.
NVRO
| $713K | 0.36% |
11,000
-117,765
| -91% | -$7.33M |
2019 Q1
1 quarter
|
|
36
United Therapeutics
UTHR
$23.3B
| $671K | 0.34% |
+8,600
| New | +$804K |
2019 Q2
0 quarters
|
|
37
DELISTED
Cidara Therapeutics
CDTX
| $603K | 0.3% |
17,948
+6,935
| +63% | +$288K |
2017 Q4
6 quarters
|
|
38
DELISTED
Kezar Life Sciences
KZR
| $264K | 0.13% |
+3,422
| New | +$532K |
2019 Q2
0 quarters
|
|
39
Neurogene
NGNE
$431M
| $9K | ﹤0.01% |
182
-1,233
| -87% | -$63.4K |
2018 Q2
4 quarters
|
|
40
CALL
Aldeyra Therapeutics
ALDX
$54.3M
| – | – |
-162,300
| Closed | -$1.47M | – |
|
41
Avalo Therapeutics
AVTX
$644M
| – | – |
-40
| Closed | -$665K | – |
|
42
Enanta Pharmaceuticals
ENTA
$336M
| – | – |
-709
| Closed | -$68K | – |
|
43
MacroGenics
MGNX
$218M
| – | – |
-107,560
| Closed | -$1.93M | – |
|
44
MeiraGTx Holdings
MGTX
$955M
| – | – |
-91,317
| Closed | -$1.57M | – |
|
|
45
CALL
DELISTED
NEVRO CORP.
NVRO
| – | – |
-70,000
| Closed | -$4.38M | – |
|
|
WAGE
46
DELISTED
WageWorks, Inc.
WAGE
| – | – |
-115,926
| Closed | -$4.38M | – |
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q2 2019 Portfolio in Review
As of Q2 2019, Prosight Management held 46 positions worth $198M, down 13% from $229M the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Prosight Management withdrew a net $17.6M in Q2 2019, closing 7 positions and reducing 18 holdings. Its most notable exit was WageWorks, Inc., an estimated $4.38M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 90% a quarter earlier, followed by Technology and Miscellaneous.
Against the trend, Prosight Management opened a new position in Q32 Bio worth $7.22M.
- Prosight Management's largest Q2 2019 buy was Q32 Bio: 20,503 shares worth $7.22M.
- Prosight Management added most to Kura Oncology in Q2 2019, an estimated $11.5M increase.
- Prosight Management's biggest Q2 2019 reduction was Cigna, cutting an estimated $16.7M.
- Prosight Management fully exited WageWorks, Inc. in Q2 2019, selling an estimated $4.38M.
- Prosight Management's ten largest holdings make up 62% of its $198M portfolio in Q2 2019.
- Prosight Management opened 8 new positions and closed 7 in Q2 2019.
- Prosight Management's portfolio value fell 13% quarter-over-quarter to $198M.
Based on Prosight Management's 13F filing for Q2 2019, filed 14 Aug 2019.